Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EPS (Basic) (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed EPS (Basic) for 16 consecutive years, with -$0.17 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) rose 91.87% year-over-year to -$0.17, compared with a TTM value of $1.41 through Sep 2025, up 131.83%, and an annual FY2024 reading of -$0.27, up 70.33% over the prior year.
  • EPS (Basic) was -$0.17 for Q3 2025 at China Pharma Holdings, down from -$0.16 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.98 in Q4 2024 and bottomed at -$3.72 in Q4 2022.
  • Average EPS (Basic) over 5 years is -$0.47, with a median of -$0.24 recorded in 2025.
  • The sharpest move saw EPS (Basic) tumbled 2166.67% in 2021, then skyrocketed 371.23% in 2024.
  • Year by year, EPS (Basic) stood at -$0.68 in 2021, then tumbled by 447.06% to -$3.72 in 2022, then surged by 80.38% to -$0.73 in 2023, then surged by 371.23% to $1.98 in 2024, then tumbled by 108.59% to -$0.17 in 2025.
  • Business Quant data shows EPS (Basic) for CPHI at -$0.17 in Q3 2025, -$0.16 in Q2 2025, and -$0.24 in Q1 2025.